Biocon rises after its arm launches HULIO injection in United States
Biocon is currently trading at Rs. 264.20, up by 0.80 points or 0.30% from its previous closing of Rs. 263.40 on the BSE.
The scrip opened at Rs. 266.60 and has touched a high and low of Rs. 270.40 and Rs. 263.65 respectively. So far 110754 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 341.50 on 19-Jul-2022 and a 52 week low of Rs. 191.60 on 21-Mar-2023.
Last one week high and low of the scrip stood at Rs. 270.40 and Rs. 243.65 respectively. The current market cap of the company is Rs. 31821.90 crore.
The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 22.10% and 17.27% respectively.
Biocon’s subsidiary -- Biocon Biologics has launched HULIO (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), in the United States after five years of experience in Europe and two years in Canada.
Biocon Biologics, which recently announced its acquisition of Viatris’ global biosimilars business, has secured multiple biosimilar approvals in the U.S., Europe, and over 100 countries across the globe. With the acquisition of Viatris’ biosimilars business, Biocon Biologics can now help provide patients and healthcare professionals with more accessible and affordable treatment options in diabetes, cancer and immunology therapeutic areas.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
